|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.96 USD | -0.62% |
|
+3.58% | +72.80% |
| 04-09 | US CDC delays publishing report showing COVID vaccine benefits, WaPo reports | RE |
| 04-09 | US CDC delays publishing report showing Covid-19 vaccine benefits, Washington Post reports | RE |
| Capitalization | 20.21B 17.22B 15.93B 15B 27.94B 1,880B 28.52B 187B 73.14B 903B 75.84B 74.24B 3,216B | P/E ratio 2026 * |
-7.15x | P/E ratio 2027 * | -11.2x |
|---|---|---|---|---|---|
| Enterprise value | 16.35B 13.92B 12.89B 12.13B 22.6B 1,520B 23.06B 151B 59.15B 730B 61.34B 60.04B 2,601B | EV / Sales 2026 * |
7.84x | EV / Sales 2027 * | 7.01x |
| Free-Float |
90.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | -0.62% | ||
| 1 week | +3.58% | ||
| Current month | +0.31% | ||
| 1 month | -7.31% | ||
| 3 months | +48.57% | ||
| 6 months | +89.94% | ||
| Current year | +72.80% |
| 1 week | 47.4 |  | 52.89 |
| 1 month | 47.14 | | 56.51 |
| Current year | 29.81 | | 59.55 |
| 1 year | 22.28 | | 59.55 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 31/05/2018 |
Noubar Afeyan
CHM | Chairman | 62 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | +3.58% | +108.00% | -68.18% | 20.34B | |
| -2.47% | -1.70% | +37.06% | -9.09% | 78.8B | |
| +1.18% | +3.97% | +104.23% | +219.62% | 60.53B | |
| -0.57% | +57.10% | +57.10% | +57.10% | 49.49B | |
| -0.74% | +0.19% | -42.43% | -53.63% | 47.58B | |
| -2.34% | -2.46% | +52.56% | -38.85% | 25.99B | |
| +0.85% | -3.28% | +102.52% | +130.77% | 19.43B | |
| -0.92% | +0.15% | +74.13% | +29.95% | 19.3B | |
| +1.04% | +1.35% | +62.09% | +61.96% | 14.9B | |
| -1.23% | +1.97% | +130.86% | +395.61% | 14.64B | |
| Average | -0.58% | +0.77% | +68.61% | +72.53% | 35.1B | |
| Weighted average by Cap. | -0.75% | +1.12% | +56.59% | +57.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.08B 1.78B 1.64B 1.55B 2.88B 194B 2.94B 19.28B 7.54B 93.11B 7.82B 7.66B 332B | 2.53B 2.16B 2B 1.88B 3.5B 236B 3.57B 23.43B 9.17B 113B 9.51B 9.3B 403B |
| Net income | -2.76B -2.35B -2.18B -2.05B -3.82B -257B -3.9B -25.56B -10B -123B -10.37B -10.15B -440B | -1.81B -1.54B -1.43B -1.35B -2.51B -169B -2.56B -16.77B -6.56B -80.99B -6.81B -6.66B -289B |
| Net Debt | -3.86B -3.29B -3.05B -2.87B -5.34B -359B -5.45B -35.75B -13.99B -173B -14.5B -14.2B -615B | -2.44B -2.08B -1.93B -1.81B -3.38B -227B -3.45B -22.61B -8.85B -109B -9.17B -8.98B -389B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/04/26 | 50.96 $ | -0.62% | 6,275,534 |
| 09/04/26 | 51.28 $ | -1.57% | 4,436,301 |
| 08/04/26 | 52.10 $ | +3.97% | 4,859,872 |
| 07/04/26 | 50.11 $ | +2.75% | 4,301,702 |
| 06/04/26 | 48.77 $ | -0.87% | 3,488,547 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition